

HLS Therapeutics Inc.

## **HLS Therapeutics to Host Q1 2019 Financial Results Conference Call**

TORONTO, April 25, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its first quarter 2019 financial results by press release at 6:30 a.m. Eastern Time on Thursday, May 9, 2019. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Financial Officer.

### **CONFERENCE CALL DETAILS**

DATE: Thursday, May 9, 2019

TIME: 8:30 a.m. Eastern Time

DIAL-IN NUMBER: (888) 231-8191 or (647) 427-7450

WEBCAST LINK: <https://event.on24.com/wcc/r/1987816/76C621B2E222AE96A4EE50B4350FECB5>

TAPED REPLAY: (855) 859-2056 or (416) 849-0833

REPLAY PASSCODE: 1739143

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at [www.hlstherapeutics.com](http://www.hlstherapeutics.com). Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast. The taped replay will be available for 14 days and the archived webcast will be available for 90 days.

### **ABOUT HLS THERAPEUTICS INC.**

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

SOURCE HLS Therapeutics Inc.

For further information: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, [dave.mason@loderockadvisors.com](mailto:dave.mason@loderockadvisors.com); Gilbert Godin, President and Chief Operating Officer, HLS Therapeutics Inc., (484) 232-3400 ext101, [g.godin@hlstherapeutics.com](mailto:g.godin@hlstherapeutics.com)

---

<https://hlstherapeutics.investorroom.com/2019-04-25-HLS-Therapeutics-to-Host-Q1-2019-Financial-Results-Conference-Call>